Market Overview

OPKO Health: Q3 Earnings Insights


Shares of OPKO Health (NASDAQ:OPK) fell 6.4% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 144.44% year over year to $0.04, which were in line with the estimate of $0.04.

Revenue of $428,100,000 higher by 87.11% from the same period last year, which beat the estimate of $374,360,000.


Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Oct 29, 2020

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $6.47

Company's 52-week low was at $1.12

Price action over last quarter: down 23.40%

Company Description

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.


Related Articles (OPK)

View Comments and Join the Discussion!

Posted-In: Earnings